A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling.

J Matthijs MollJinpei KumagaiMartin E van RoyenWilma J TeubelRobert J van SoestPim J FrenchYukio HommaGuido JensterRonald de WitThomas A Kirkland

Published in: The Prostate (2019)

Activation of the AR by clinically relevant levels of Preg and Prog accumulating in abiraterone-treated patients may act as a driver for CRPC. These data provide a scientific rationale for combining CYP17A1 inhibitors with antiandrogens, particularly in patients with overexpressed or mutated-AR.

Keyphrases

prostate cancer
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
clinical trial
peritoneal dialysis
radical prostatectomy
patient reported outcomes
patient reported